What should I do if I become resistant to Palbociclib?

Palbociclib (Palbociclib) appears in HR+, HER2- metastatic breast cancer cells. CDK4/6 inhibition acts directly downstream of endocrine therapy targets, and cross-treatment resistance may develop as patients progress on hormone therapy. Endocrine-resistant tumors can maintain sensitivity to CDK4/6 inhibition and have better efficacy in patients receiving palbociclib combined with endocrine therapy.

If a patient develops drug resistance after using palbociclib, doctors will adjust the treatment plan based on the specific situation. This may include changing the medication dose, using other medications in combination, or switching to an alternative treatment regimen, and, if applicable, consideration of participation in relevant clinical trials. In addition to medication, lifestyle changes can also play an important role in breast cancer management, including maintaining a healthy diet, increasing physical activity, and reducing stress. However, everyone’s physique is different and their resistance to drugs is also different. If you feel unwell, please inform your doctor in time.

The original drug of palbociclib has been launched in China and has entered the scope of Class B medical insurance, but reimbursement is limited to patients who meet the indications. The price of each box may be more than more than 4,000 yuan. The price of palbociclib's original drug, 125mg*21 capsules, per box sold overseas may be more than RMB 10,000 (the price may fluctuate due to exchange rates). There are also generic palbociclib drugs produced in other countries. The price of 125mg*21 tablets produced by a Bangladeshi pharmaceutical factory may be around a few hundred yuan per box (the price may fluctuate due to the exchange rate). The price is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.